Par Pharmaceutical Companies Inc.

Par Pharmaceutical Companies, Inc. develops, licenses, manufactures, markets, and distributes generic drugs in the United States. It operates through two segments, Par Pharmaceutical and Par Specialty Pharmaceuticals. The Par Pharmaceutical segment markets generic products under Par Pharmaceutical brand name and sterile products under the Par Sterile brand. This segment also offers dosage forms and delivery systems, including oral solids and alternate dosage forms, such as oral solids, injectables, topicals, nasal sprays, ophthalmics, films, and transdermal patches. In addition, this segment markets pharmaceutical products, including Exforge, Lovaza, Precedex, Lamictal XR, Luvox CR, and Focalin XR; and authorized generic products, including entecavir, budesonide nasal spray, and digoxin, as well as metoprolol succinate ER, budesonide, candesartan cilexetil, rizatriptan, and modafinil. The Par Specialty Pharmaceuticals segment focuses on the marketing and distribution of Nascobal Nasal Spray, a prescription vitamin B12 treatment indicated for maintenance of remission in certain pernicious anemia patients; and Megace ES for the treatment of anorexia, cachexia, or any unexplained significant weight loss in patients with a diagnosis of AIDS. The company markets its generic products to wholesalers, drug store chains, supermarket chains, mass merchandisers, distributors, mail order accounts, hospitals, and the government. Par Pharmaceutical Companies, Inc. was founded in 1978 and is based in Chestnut Ridge, New York. Par Pharmaceutical Companies Inc. operates as a subsidiary of Par Pharmaceutical Holdings, Inc.